FutureMeds opens first clinical trial site in Wroclaw, Poland
Updated: Jan 24
FutureMeds, a new independent Site Management Organisation, has opened its first site in Wroclaw, Poland. The site is the first of a number of planned new site openings across Europe as FutureMeds looks to establish itself as a key provider of services to CROs and pharma companies.
With an initial focus on primary care trials, FutureMeds aim to recruit patients and run clinical trials in therapy areas including cardiovascular, rheumatology, respiratory, NASH, diabetes, CNS, dermatology, women’s health, metabolic disease and vaccines.
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.